eTheRNA
Manufacturing · Belgium · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Galileilaan 19, Niel, Flanders, 2845, Be...Phone Number
+32 33691740Website
www.etherna.beRevenue
$14.8 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About eTheRNA
eTheRNA, founded in 2013 and headquartered in Flanders, Belgium, is a clinical-stage Belgian biotech company applying mRNA-based immunotherapies to the treatment of cancer and infectious diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is eTheRNA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if eTheRNA is spiking on competitors!
Product Launch: Get notified when eTheRNA launches new products
Click to see if eTheRNA had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at eTheRNA
eTheRNA, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on eTheRNA recently announced quarterly report
Check if eTheRNA has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once eTheRNA has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined eTheRNA as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
eTheRNA is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
eTheRNA is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about eTheRNA.
eTheRNA financials insights
Gather financial insights about eTheRNA, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$26.7M
2022
Series B
$77M
eTheRNA Tech Stack
A closer look at the technologies used by eTheRNA
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Person-Based
Open Position
Executive Move
Executive Moves, Board of Directors
eTheRNA News & Media
Valerio Therapeutics Announces Signing of Definitive Agreements for ... - Yahoo Finance Singapore
VILLEJUIF, France, August 24, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the signing of a definitive share purchase agreement (the "SPA") and of the related contribution agreement (the "Contribution Agreement") for the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"), basAntonin (Tony) de Fougerolles appointed as new Chair of etherna
Brings foundational experience in mRNA and LNP therapeutics given prior executive leadership roles at Moderna & Alnylam Will take an active role in expanding partnerships with biopharma Integrated partnership offering to customers remains etherna's key differentiator – Proprietary...Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
BARCELONA, Spain & NIEL, Belgium--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The alliance combines and leverages etherna’s innovative proprietary mRNA capabilities and LNP formulations with Almirall’s leading expertise in medical dermmRNA/LNP technology platform company etherna names Bernard Sagaert as Chief Executive Officer and Marijn Dekkers as Chairman of the Board
Sagaert's CEO appointment follows his successful interim period implementing etherna's new partnership-driven business strategy. Sagaert joined etherna in 2017 and brings extensive operational and strategic experience in the life sciences industry. Dekkers, who is the founder of...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding eTheRNA
Sign Up For FreeTo access detailed company insights
eTheRNA, founded in 2013 and headquartered in Flanders, Belgium, is a clinical-stage Belgian biotech company applying mRNA-based immunotherapies to the treatment of cancer and infectious diseases.... Read More
